pterostilbene
Small moleculeexperimental
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a stilbenoid chemically related to resveratrol. In plants, it serves a defensive phytoalexin role. — Wikipedia
Clinical trial activity
12 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01267227)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(/C=C/c2ccc(O)cc2)cc(OC)c1- Mol. weight
- 256.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPterostilbene ↗
- ChEMBLCHEMBL83527 ↗
Also known as
- 3',5'-dimethoxy-4e-stilbenol
- 3,5-dimethoxy-4'-hydroxy-trans-stilbene
- 3',5'-dimethoxy-4trans-stilbenol
- 3',5'-dimethoxy-resveratrol
- 4-((e)-2-(3,5-dimethoxyphenyl)ethenyl)phenol
- 4trans-(2-(3,5-dimethoxyphenyl)ethenyl)phenol
- phenol, 4-((1e)-2-(3,5-dimethoxyphenyl)ethenyl)-
- pterostilbene
- pterostilbene
- pterostilbene
- pterostilbene, (e)-
- trans-3,5-dimethoxy-4'-hydroxystilbene
- trans-pterostilbene
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07024966 | N/A | Aug 1, 2025 | Circe, S.L., Eurecat |
| NCT05561075 | N/A | Oct 31, 2022 | Circe, S.L., Eurecat |
| NCT05095571 | N/A | Oct 7, 2021 | Elysium Health, University of Bergen |
| NCT04841499 | N/A | Apr 5, 2021 | Elysium Health, University of South Alabama |
| NCT04562831 | N/A | Oct 7, 2020 | Elysium Health, University of Bergen |
| NCT04342975 | Phase 2 | Jul 31, 2020 | Elysium Health, Mayo Clinic |
| NCT04050358 | Phase 1 | Jul 30, 2019 | Elysium Health, University of Exeter |
| NCT03754842 | N/A | Feb 12, 2019 | Aarhus University, University of Copenhagen |
| NCT03671811 | Phase 2 | Dec 18, 2018 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03635411 | Phase 1 | Sep 30, 2018 | University of Pennsylvania |
| NCT03513523 | N/A | Apr 18, 2018 | Elysium Health, Nutrasource Diagnostics, Tufts University |
| NCT01267227 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2010 | University of Mississippi |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elysium Health | For profit | 6 | 2 | 3 | 2018 |
| Circe, S.L. | For profit | 2 | 0 | 1 | 2022 |
| Eurecat | For profit | 2 | 2 | 1 | 2022 |
| University of Bergen | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| Nutrasource Diagnostics | For profit | 1 | 0 | 1 | 2018 |
| Tufts University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Exeter | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Mississippi | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of South Alabama | Academic/Hospital | 1 | 1 | 1 | 2021 |
15 organizations
Page 1 / 1